Top 50 Life Science Startup Investors in Europe in October 2024

Investor	Life Science Europe investments
SOSV	20
Sofinnova Partners	16
Parkwalk Advisors	16
UK Innovation & Science Seed Fund	12
Oxford Science Enterprises	12
Bpifrance	9
Kurma Partners	9
Development Bank of Wales	8
Jonathan Milner	8
Centre for the Development of Industrial Technology (CDTI)	8
GM&C Life Sciences Fund	7
Bullnet Capital	7
Archangels	7
Nina Capital	7
Capital Cell	7
Seventure Partners	7
Oxford Science Enterprises	7
24 Haymarket	7
Selvedge Venture	6
Angels in MedCity	6
PMV	6
Verve Ventures	6
APEX Ventures	6
Advent Life Sciences	6
Novo Holdings	6
Newable Private Investing	6
Idinvest Partners	6
Scottish Investment Bank	6
Scottish Enterprise	6
Enterprise Ireland	6
Boehringer Ingelheim Venture Fund	5
R42 Group	5
Deepbridge Capital	5
HTGF \| High-Tech Gruenderfonds	5
AIB Seed Capital Fund	5
Epidarex Capital	5
Meusinvest (Noshaq)	5
Omnes Capital	5
IFB Innovationsstarter	5
Amino Collective	5
coparion	5
Amadeus Capital Partners	5
Formic Ventures	4
IQ Capital	4
Paca Investissement	4
Mercia Fund Managers	4
ENISA	4
Oxford Capital	4
Angels 5K	4
Techstart Ventures	4

SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.

Investment focus

Biotechnology, Health Care, Software
Seed, Convertible Note, Pre-Seed
United States, India, United Kingdom

Portfolio highlights

MixRift — MIXRIFT - game developers specialized in Mixed Reality
unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.

Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
France, United States, United Kingdom

Portfolio highlights

deepc — The Radiology AI Platform - Your effortless access to AI
Asceneuron — Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease. By focusing on areas of high unmet medical need, Asceneuron aspires to become a leading biotech company specialized in small molecule drug discovery for neurodegenerative diseases.Tauopathies are currently untreatable neurodegenerative diseases thatrapidly progress towards debilitating conditions. The appearance of deposits of the microtubule-associated tau protein as e.g. neurofibrillary tangles in neurons of the brain is a common feature of tauopathies that is shared with Alzheimer’s disease. Neuronal tau deposits are known to be a major contributor to neurodegeneration and mutations in the tau gene are causative of the tauopathy fronto-temporal dementia and parkinsonism linked to chromosome 17 (FTDP-17).Due to increasing life expectancy, Alzheimer’s disease is viewed as one of the largest healthcare problems of this century, imposing a major economic burden on societies in the Western and developing world. Current treatment options provide limited benefits supporting the urgent need for more efficacious and better tolerated medicines that address symptomatic relief as well as disease progression.
Micropep Technologies — Micropep Technologies developes a non-GMO new generation of bioherbicides and biostimulants. Micropep, founded in 2016 in Toulouse, focuses on bioherbicides and biostimulants. The company uses plants’ natural molecules, called “micro-peptides”, to temporarily control expression of their genes and regulate plant growth but leaving their DNA intact.The company currently works on four development programs: germination, flowering, growth, and weed control.

Parkwalk is a London-based fund management firm. Parkwalk invests in UK technology companies that have IP backing and freedom to operate, generally spun out of UK universities. Their funds seek to generate capital gains for their investors, enhanced by the attractive tax relief provided by EIS. Parkwalk entered this investment sector in 2009,anticipating a wave of tax-efficient incentives launched by the UK Government to stimulate innovative emerging technology companies and thereby help drive economic growth.Parkwalk utilises academic, technology transfer, venture capital and personal networks developed over many years to gain access to the highest calibre deal-flow. In 2017 Parkwalk joined forces with IP Group plc, a leading intellectual property commercialisation company that is listed on the Main Market of the London Stock Exchange under the ticker symbol IPO. As at March 2019 the combined group has net assets of £1.2bn.

Investment focus

Biotechnology, Health Care, Software
Seed, Series A, Series B
United Kingdom, United States, Philippines

Portfolio highlights

Evoralis — Utilise Our Innovative Enzymes to Efficiently Recycle Plastics Into High-Quality Raw Materials
PhoreMost — PhoreMost is a new-model drug discovery company based in Cambridge, UK: Using its core expertise to open up new ‘druggable’ target space and working with a global network of co-invested academic and industrial collaboration partners, we aim to bring a wide array of novel ‘targeted’ therapies more efficiently to market and pass these cost savingsonto patients.
OW Smell Made Digital — OW Smell Made Digital offers software and hardware solutions for controlling smell.

UKI2S, formally the Rainbow Seed Fund, is an investment fund backed by the government, providing seed funding to science & technology start-ups and SMEs

Investment focus

Biotechnology, Health Care, Medical
Seed, Funding Round, Series A
United Kingdom, United States

Portfolio highlights

HonuWorx — HonuWorx is a technology company providing autonomous systems aimed at lowering both expenses and the environmental impact of operating robotic systems. The company's software technology is an edge-cloud architected communications and control platform that enables geographically distributed stakeholders to see data, collaborate, supervise, andcontrol robotic systems that are beyond line-of-sight.
Solasta Bio — Solasta Bio develops environment-friendly products that meet a global need for new and effective crop protection.
Wave Photonics — Wave Photonics utilizes computational techniques to accelerate integrated photonics product designs.The company is developing a platform that provides optimized designs and streamlined integration between the supply chain using a software tool for predicting the performance and variation of a component for a given fabrication process and anoptimizer to generate a foundry-specific component library.Wave Photonics is headquartered in Bristol, Bristol.

Oxford Science Enterprises is the university-partnered venture firm. We work with the University of Oxford to build companies that create fundamental technologies: science-based businesses capable of tackling the planet’s toughest problems. We invest in life science, AI and software, healthcare, and deep tech to create companies taking onchallenges like nuclear fusion, quantum computing and developing treatments and cures for infectious diseases. Founded in 2015, we’ve raised over £600M to create a world-class technology ecosystem, and combine our deep experience with a network of investors, entrepreneurs and sector-experts to find co-investment, build businesses, and hire senior management talent.

Investment focus

Health Care, Biotechnology, Software
Seed, Series A, Funding Round
United Kingdom, United States, Finland

Portfolio highlights

FluoRok — By employing our patented technology, we can produce fluorochemicals without the production of toxic and highly dangerous hydrofluoric acid
Fractile — Fractile is building chips to run large language models two orders of magnitude faster. Existing hardware is good for training LLMs, but very poorly suited to subsequent inference of the trained model, which is increasingly the dominant workload. A network’s weights need to be moved onto a chip once per word generated, and this movement takes a fewhundred times longer than the subsequent computations themselves. Fractile’s revolutionary approach to fusing computation with memory eliminates this bottleneck, and can scale to allow running the world’s largest models at a global scale.
Amber Therapeutics — Developing intelligent bioelectrical therapies that can adapt, respond and learn from each person's individual physiology

Bpifrance provides financial solutions for companies that are booting up the listing on the stock exchange and credit equity. It includes OSEO, CDC Entreprises, FSI, and FSI Regions to offer in your area of financial solutions at every stage of the life of your business.Bpifrance was founded in 2012 and is based in Maisons-alfort, Ile-de-France,France.

Investment focus

Software, Information Technology, Health Care
Funding Round, Seed, Series A
France, United States, Switzerland

Portfolio highlights

Inbolt — InBolt has developed the world’s smallest and most efficient 3D camera tracking system. Their first product is a hardware module / device that an operator can plug onto all manual tools such as a drill, a screwdriver or a torque wrench. Once on the tool, it guides the operator, validates the completion of a task in real time and registers allthe completion parameters.
Oderis — Oderis helps corporate and private equity clients with transaction advisory, business valuation, consulting and financial assistance.
VELA — VELA is an innovative 100% wind-powered maritime transport. It has been working to address the climate emergency by providing a creative, sustainable, and socially responsible maritime transportation solution.

Kurma Partners is a management company based in Paris, specializing in the financing of innovation in healthcare and biotechnology, from pre-creation to development capital. Kurma Partners, which manages the Kurma Biofund I, II funds and the Kurma Diagnostics fund, is one of the main players in the financing of therapeutic and medical innovationsin Europe, particularly through links with many institutes. research and prestigious hospitals.

Investment focus

Health Care, Biotechnology, Pharmaceutical
Series A, Series B, Seed
France, Switzerland, Spain

Portfolio highlights

SciRhom — SciRhom GmbH is a biotech company that translates science into the preclinical and early clinical development of novel biopharmaceuticals for the treatment of life-threatening autoimmune diseases. Based on longstanding academic research and a well-established network of experts, SciRhom was founded in 2016 through a collaboration between academicand industry scientists with profound experience in antibody development.
PanTera — PanTera wants to bring a new hope to cancer patients by enabling the widespread use of radiopharmaceuticals for personalised treatment of tumors
Spotlight Medical — Spotlight Medical is a precision medicine company striving to free all patients from cancer through a better understanding of each patient’s unique disease. We develop advanced AI tests that enhance treatment selection by leveraging decades of patient data. This ensures personalized and effective care for each individual, significantly improvingpatient outcomes and quality of life. By closely collaborating with physicians, we create impactful tests that address critical unmet clinical needs, opening a new era in cancer care.

Development Bank of Wales is formed in 2001 by the Welsh Assembly Government. Development Bank of Wales is an independent company, providing commercial funding to Welsh SMEs. They invests private and public funds, including EU funds.

Investment focus

Software, Health Care, Biotechnology
Seed, Funding Round, Debt Financing
United Kingdom, Australia, United States

Portfolio highlights

PlantSea — PlantSea manufactures and develops sustainable products using seaweed and aquaculture materials. It offers bioplastics items as biodegradable alternatives. PlantSea is based in Gaerwen, England.
Menna — Be smarter about money and grow faster with Menna. Take control of your business finances today!
Awen Oncology — Delivering first-in-class therapeutics that target novel, undrugged cancer-specific factors, offering new hope for patients around the world.

Having worked in the life sciences industry for over ten years as an academic researcher, Jonathan identified the market opportunity for supplying high quality antibodies to support protein interaction studies and, in 1998, founded Abcam with David Cleevely and Professor Tony Kouzarides. Jonathan is a Non-Executive Director of Horizon DiscoveryGroup plc, The Evolution Education Trust, GeoSpock Ltd and Sydicate Room Group Ltd. He is also Chairman of Axol Bioscience Ltd, PhoreMost Ltd, Repositive Limited, Definigen Limited and Cambridge Allergy Ltd. Jonathan holds an executive director position at Meltwind Limited, being a designated member of Meltwind Advisory LLP. Jonathan is an experienced entrepreneur and investor and is passionate about supporting UK life science and high-tech start-ups. He has provided considerable investment and support to over 30 companies and has assisted three AIM IPOs.

Investment focus

Biotechnology, Health Care, Medical
Seed, Series A, Series B
United Kingdom, United States, Canada

Portfolio highlights

PhoreMost — PhoreMost is a new-model drug discovery company based in Cambridge, UK: Using its core expertise to open up new ‘druggable’ target space and working with a global network of co-invested academic and industrial collaboration partners, we aim to bring a wide array of novel ‘targeted’ therapies more efficiently to market and pass these cost savingsonto patients.
Constructive Bio — Constructive is a ground-breaking method for creating wholly artificial genomes and rewriting the genetic code of living things.
LIfT BioSciences — LIfT BioSciences is a socially-minded Biotech start-up that develops a portfolio of potentially life-saving immuno-oncology cell therapies for different solid tumors using its innate immunity platform. Its goal is to create a Cell Bank with the potential to cure cancer, using Leukocyte Infusion Therapy.LIfT BioSciences was founded in 2016 andheadquartered in London, England.

The Center for Industrial Technological Development (CDTI) is a public corporation under the Ministry of Economy and Competitiveness, which promotes innovation and technological development of Spanish companies. Is the entity which channels requests for funding and support to projects I + D + i of Spanish companies in the national andinternational levels. The CDTI has a staff of more than 300 people formed three quarters of engineers and graduates. Although the bulk of the infrastructure of the CDTI is located in Madrid, the Centre offers Spanish companies a strategic network of offices and representatives abroad (Japan -SBTO (Spain Business and Technology Office) - Belgium -SOST (Spain Office of Science and Technology) and Permanent Secretariat Eureka-, Brazil -FINEP (Financier of Studies and Projects) -, Korea, Chile, Morocco, China, India, Mexico and USA) to support them in their technological activities of type int .

Investment focus

Biotechnology, Health Care, Software
Funding Round, Seed, Grant
Spain, United States, France

Portfolio highlights

SOLATOM — SOLATOM sells solar steam to industries with thermal processes. Solatom is a solar concentrator designed for generating high temperature heat (steam, hot water or thermal oil) in industrial processesSolatom's modules are formed by rows of mirrors that track the sun , reflecting the sunlight on a vacuum tube. The fluid circulating through thetube absorbs the reflected energy producing an increase in the temperature of the fluid (up to 300 ° C ). Each module has a nominal power of 15kW thermal. When more capacity is needed, the modules are joined together, increasing the total power of the plant. The system is designed for be deployed on the rooftop, being its specific weight less than 23 kg/m 2 .
IENAI SPACE — IENAI SPACE develops efficient ionic-liquid electric propulsion systems and mission analysis for nano-satellites. The company provides propulsion modules customized for each particular platform and mission, from 2U to 12U, from RAAN-spacing to Earth-Moon transits or de-orbiting.Its versatile Tailored Taylor Thruster is highly scalable in specificimpulse and thrust. It is based on a novel iteration of electrospray thrusters, which boast high theoretical efficiencies for electric propulsion technologies in the low power range. In combination with its decreased form factor, meaning less propellant on-board, making this technology attractive in constrained volumes.IENAI SPACE was founded in 2019 and is headquartered in Madrid, Spain.
Trovant Technology — Trovant Technology specializes in the development of bio-based technologies for organic waste treatment and valorization, transforming this waste into bioenergy. They develop proprietary technology and tailor-made solutions, always keeping the market in mind. At the moment they are focusing on biogas upgrading and biomethane with UBI - BiologicalIntegral Biogas Upgrading.

The GM&C Life Sciences Fund is a seed and early stage venture capital fund targeting life sciences businesses located in the Greater Manchester and Cheshire & Warrington region. The Fund is managed by Catapult Venture Managers ("Catapult Ventures").The Fund is based at Alderley Park, which is well recognised as a site ofnational importance, being the largest life sciences campus of its kind in the UK with more than 500,000 sq. ft. of top-end laboratory and related space and facilities. Until recently, the Park was the R&D headquarters for AstraZeneca.Since 2002, Catapult Ventures has backed a significant number of companies across a broad range of life sciences, including therapeutics (such as Abzena and Oxford BioTherapeutics), medical devices (such as Monica Healthcare and Probe Scientific), contract research organisations (such as R5 Pharmaceuticals and FDAS), diagnostics developers (such as Lumora and Biofortuna), as well as developers of technology used in healthcare applications (such as Oxford Cryosystems and Accutronics). The Fund is the result of a collaboration between Cheshire and Warrington Enterprise Partnership, Greater Manchester Combined Authority, Cheshire East Council, and Manchester Science Partnerships.

Investment focus

Health Care, Biotechnology, Medical
Seed, Funding Round, Series A
United Kingdom, Italy, Germany

Portfolio highlights

ScubaTx — ScubaTx is a breakthrough organ preservation device organ transplant. The ScubaTx device will leverage world-leading expertise in software design to commercialise a proven but unexploited organ preservation technique, Persufflation. ScubaTx will offer healthcare providers significant net savings, an
Flynotes — Flynotes is a digital software platform helping dentists deliver personalised patient care
QV Bioelectronics — Manchester-based start-up QV Bioelectronics is developing innovative electrotherapy devices for the treatment of certain types of brain tumours.

Independent Venture Capital Firm specialized in high technology Spanish start-ups. Helping tech entrepreneurs during the early stages of their company to build successful businesses

Investment focus

Software, Information Technology, Enterprise Software
Funding Round, Seed, Series A
Spain, United States, Mexico

Portfolio highlights

MLCode — Accelerated by massive AI/ML adoption, Data is to become the most critical resource for Enterprises. MLCode vision is to protect that Data. MLCode: Data Security Automation.
Inspiration-Q — Inspiration-Q focuses on developing and commercializing software solutions inspired by quantum computing for financial applications.
Mapsi Photonics — Mapsi Photonics focuses on developing macroporous silicon infrared filters for industrial applications like gas identification and thermal vision, aiming to improve performance, cost, resolution, operational range, and environmental footprint.

Established in 1992. Archangels is the oldest continuously operating business angel syndicate in the World. Investing in IP-rich tech & life sciences companies in Scotland, UK.

Investment focus

Software, Biotechnology, Health Care
Funding Round, Seed, Series A
United Kingdom, United States

Portfolio highlights

Bio-Images Drug Delivery — BDD Pharma combine drug delivery expertise and clinical capabilities to accelerate product development pipelines, enable life cycle management and new innovative pharmaceutical products. Rapid parallel clinical testing with SWIFT significantly reduces time from product concept to clinical success.
1inhaler — 1inhaler operates as a developer of drug delivery device.
iGii — Integrated Graphene enable better products with a revolutionary design for manufacture process producing the world's highest quality pure 3D Graphene Foam, Gii.

We deploy early stage capital to fuel the growth of need-driven health technology companies.

Investment focus

Health Care, Artificial Intelligence, Software
Seed, Pre-Seed, Series A
United States, United Kingdom, Austria

Portfolio highlights

Noah Labs — Noah Labs is a compant that creates AI-powered software solutions for medical care and research that help diagnose, manage illnesses, and guide interventions.
Rivia — Integrated Clinical Trial Intelligence. Drive therapeutic evaluation and trial management with real-time insights.
Lillian Care — Lillian is building a nationwide network of health facilities in Germany.

Capital Cell is a pan-European crowdinvesting platform for Biotech & Life Sciences companies. Mixing VC, business angels, accredited investors and the power of the Crowd, the company is building a global meeting point for companies and researchers working, fostering and financing tomorrow’s medical science.

Investment focus

Health Care, Biotechnology, Medical
Equity Crowdfunding, Funding Round, Seed
Spain, United States, United Kingdom

Portfolio highlights

Exheus — Exheus tells everything that you need to know to take maximum care of yourself and avoid risks to your health, exheus is much more than a DNA test that only indicates which genes you have.
MediQuo — MediQuo is a hospital in your pocket, connecting patients and professionals for any health interaction. Healthcare today has 75% of unnecessary medical visits that could be taken in the distance, and the vast majority of health professionals are using messaging platforms such as WhatsApp to communicate with patients or other health professionals.MediQuo is a chat-based app specialised in health, GDPR and health data compliant, giving professionals time control, incorporating patient medical history and phone privacy. Allowing also video and audio communication. It is a place for discussion, appointments or medical consultation with your doctor or any new health professional. Also includes immediate 24/7 medical response and a network, for health information and professional discovery. We have done already 1M consultations and got 600k app downloads. Our Google Play Ratings are 4,6 (with 6k reviews). We are amongst the top health apps in Spain and Latam.
Affirma Biotech — Affirma Biotech develops new orally available immunotherapeutic drugs for the treatment of severe infections and cancer

Seventure Partners is a French venture capital firm targeting in information and communication technology, and life sciences companies. It funds innovation and participates in the entrepreneurial adventure, alongside entrepreneurs and sharing their passion.Founded in 1997, Seventure Partners is one of the European leaders in venture capital, with€ 660 million under management as of December 31, 2016. It is an active partner of innovative companies that, according to the management team, show strong growth potential and evolving in two fields of activity: Digital Technologies and Life Sciences. With more than 20 employees, including some 15 investors, Seventure Partners has a proven track record and in-depth expertise in technology, entrepreneurship, and various private equity operations.Seventure's goal is to identify and support the development of tomorrow's European leaders in order to accelerate their growth. To do this, the firm provides entrepreneurs with the expertise, networks, and know-how of its internal team of investors.

Investment focus

Biotechnology, Health Care, Software
Series A, Series B, Funding Round
France, United States, Germany

Portfolio highlights

ID5 — ID5 provides a comprehensive suite of identification services designed to improve to improve addressability and measurement across all environments
Microbiotica — Microbiotica is a developer of human microbiome therapeutics intended to discover and develop live bacterial therapeutics and biomarkers. The company's therapeutics identify gut bacteria linked to phenotype with unprecedented precision, enabling researchers to phenotype before testing of candidate bacteria in advanced human in vitro and invivo models.
Sequentia Biotech — Sequentia Biotech is a bioinformatics company that offers services for healthcare, pharma, agriculture, industry and environment.

Oxford Science Enterprises is the university-partnered venture firm. We work with the University of Oxford to build companies that create fundamental technologies: science-based businesses capable of tackling the planet’s toughest problems. We invest in life science, AI and software, healthcare, and deep tech to create companies taking onchallenges like nuclear fusion, quantum computing and developing treatments and cures for infectious diseases. Founded in 2015, we’ve raised over £600M to create a world-class technology ecosystem, and combine our deep experience with a network of investors, entrepreneurs and sector-experts to find co-investment, build businesses, and hire senior management talent.

Investment focus

Biotechnology, Health Care, Software
Series A, Seed, Series B
United Kingdom, United States, The Netherlands

Portfolio highlights

Theolytics — Theolytics is a biotechnology company harnessing viruses to combat cancer. A step-change in the oncolytic viral therapy field, our phenotypic screening Platform enables the discovery and development of efficacious, targeted candidates suitable for intravenous delivery and optimised for a chosen patient population. In addition to advancing aninternal Pipeline of programs spanning both solid and liquid tumours, we are establishing select strategic partnerships to expand and accelerate pipeline development.
Oxford Endovascular — Oxford Endovascular are developing a novel treatment for treating brain aneurysms. The Oxford technology uses a special laser-cut metal alloy which has a shape-memory. It can be posted into a catheter during surgery, inserted into the brain and opened up into a tiny tube mesh (‘flow diverter’) that fits into the natural shape of the blood vessel.This diverts the blood away from the aneurysm, allowing it to heal.
Grey Wolf Therapeutics — By targeting the ERAP proteases in the antigen presentation pathway Grey Wolf aims to change the antigen repertoire in cancer.

24Haymarket is an investment network which included several highly-experienced private equity and venture capital investors, seasoned entrepreneurs, and senior operators. Investing up to £5 million in growth companies in the UK and Europe. They invested their own capital in direct alignment with entrepreneurs and actively support their growthagenda and join the board of the companies in which they invest. Since inception in 2011, 24Haymarket has invested in more than 50 high-growth businesses.

Investment focus

Health Care, Software, Information Technology
Funding Round, Seed, Series A
United Kingdom, United States

Portfolio highlights

myGwork — The global recruitment & networking hub for LGBTQ+ professionals. Find jobs in lesbian, gay, bisexual and transgender friendly organisations. Grow your LGBTQ+ professional network. Read the latest LGBTQ+ professional news.
Previsico — Previsico is a spinOut company from Loughborough University specialising in modelling flooding in real-time, using weather predictions to make street-level flood nowcasts and forecasts. The company's mission is to be the leading global provider of cutting-edge flood prediction that saves lives and livelihoods.Its FloodMap Live producesround the clock street-level flood risk predictions and analytics. Uniquely, these are continuously modelled and updated using a combination of different weather forecasts. This allows the company to map the likelihood of short and long-term surface water events in real-time to the street level.
Huq Industries — The leading monitoring platform for footfall, dwell, catchment and traffic flows valued by government, retail and real-estate. Used by 50+ councils!

Selvedge Venture operates as a venture capital firm investing for impact in age-related medical conditions.

Investment focus

Health Care, Biotechnology, Life Science
Seed, Pre-Seed, Series A
United Kingdom, Singapore

Portfolio highlights

Mesh Bio — Mesh Bio is a digital health startup that is transforming chronic disease management through predictive analytics. Mesh Bio works with healthcare providers and stakeholders to provide innovative solutions that transform health screening and disease management. They translate clinical data and numbers into actionable insights that help patientsbetter manage their health, lifestyle and disease risks.
Ochre Bio — Ochre Bio is developing therapies for the biggest liver health challenges.
BIOS — BIOS Health is unlocking the potential of the nervous system in treating chronic disease by using AI-powered neural interfaces that can automatically read and write neural signals.

Angels in MedCity is a partnership between MedCity, London Business Angels and Angels4LifeSciences. The programme aims to introduce new people to investing and investing in the healthcare/life sciences sector via investor workshops and introduce business angels to investment opportunities from highly-selected and trained companies.With aparticular focus on drug therapies, digital health and medical device technologies, Angels in MedCity brings potential investors together with life sciences experts in a programme aimed at both people who are new to investing and experienced investors who have little or no experience in the life sciences sector. The aim is to build investor understanding in the life sciences sector and support life sciences companies to gain funding to commercialise their ideas.Angels in MedCity has created a community of investors supported through a programme of investor workshops. Using case studies and tips from experienced investors in the field, the workshops explain how to identify and structure a good deal in the life sciences sector, as well as provide expert advice on tax breaks and legal issues.

Investment focus

Health Care, Biotechnology, Medical
Seed, Funding Round, Angel
United Kingdom, United States

Portfolio highlights

Atelerix — Discover Atelerix's hypothermic hydrogels for eco-friendly, reliable cell preservation and ambient temperature shipping. Ensure fresh, viable cell samples today.
Clustermarket — The intuitive lab management system for all academic research facilities and industrial laboratories that need to efficiently manage equipment bookings.
DynamX Medical — DynamX Medical has developed a reliable and inexpensive precancer screening system for rapid tissue biopsy analysis that can be operated point-of-care by nurses.

Do and dare company

Investment focus

Software, Biotechnology, Health Care
Series A, Seed, Funding Round
Belgium, The Netherlands, United States

Portfolio highlights

Accurat — Accurat provides real-word shopper insights to support retail decision making with unprecedented accuracy. Our proprietary technology, platform and algorithms understand behaviour in high detail.
PanTera — PanTera wants to bring a new hope to cancer patients by enabling the widespread use of radiopharmaceuticals for personalised treatment of tumors
Augustine Therapeutics — Augustine, Innovative therapies for neuromuscular and neurodegenerative diseases

Verve Ventures has invested in more than 140 science and technology startups. We support visionary and resilient entrepreneurs from day one and are a reliable partner for the entire journey. We typically invest EUR 1-3m in early as well as later stage rounds of European high tech startups.

Investment focus

Health Care, Software, Biotechnology
Series A, Seed, Series B
Switzerland, Germany, France

Portfolio highlights

Cubbit — Cubbit is secure encrypted cloud storage with a difference. A distributed cloud that is 100% private and green. Join the Swarm.
Axelera AI — To accelerate computer vision in edge devices, we offer a powerful, energy-efficient, cost-effective, user-friendly AI hardware and software platform.
Puraffinity — Puraffinity develops targeted materials for water treatment, focused on forever chemicals called PFAS. Our strategic intent is to provide 1 billion people with PFAS safe water by 2030

APX Ventures offers digital solutions, including pay-per-click, custom web services, SEO, and cloud services.

Investment focus

Software, Artificial Intelligence, Health Care
Seed, Series A, Pre-Seed
Germany, Austria, United Kingdom

Portfolio highlights

sewts — Founded in 2019 and based in Munich, sewts GmbH provides cutting-edge perception software, pushing the boundaries of robotics in processing of easily deformable materials. sewts has developed and demonstrated a unique technology that uses high-precision finite element method (FEM) simulations to efficiently train machine learning algorithms. Theintelligent software solution enables countless applications in industrial automation like the handling of textiles in industrial laundries or the manufacturing of garment. sewts is backed by APEX Ventures, Bayern Kapital, High-Tech Gründerfonds, UnternehmerTUM Initiative for Industrial Innovators and a couple of highly experienced business angels.
Senisca — Developing a new generation of senotherapeutic interventions to target the diseases and aesthetic signs of ageing.
CardiaTec Biosciences — CardiaTec is a digital biotechnology venture combining the power of AI and expert talent to redesign cardiovascular drug discovery to deliver the next generation of therapeutics

Advent Life Sciences is a venture team investing in life sciences businesses. The team consists of 11 professionals with extensive scientific, medical and operational experience, and a long-standing track record of entrepreneurial and investment success across the UK, Europe and the US. The Firm invests in a range of sectors within life sciences,principally in new drug discovery, enabling technologies, and med tech. Realizations in the last three years include Algeta, Avila, CN Creative, EUSA, Micromet. Current investments include Acutus, Biocartis, Cellnovo, f2G, NeRRe,

Investment focus

Biotechnology, Health Care, Medical
Series A, Funding Round, Series B
United States, United Kingdom, France

Portfolio highlights

Argá Medtech — Developing the next generation of Pulsed Field Ablation and Irreversible Electroporation Venture-capital backed company
PIC Therapeutics — PIC Therapeutics is a biotechnology company focused on fundamentally changing how we treat cancer by developing a new generation of therapeutics based on the modulation of RNA translation.
Curve Therapeutics — Curve has developed an innovative screening platform that is transforming the discovery of first-in-class therapeutics. The platform allows functional screening of diverse, genetically encoded Microcycle™ libraries against a broad range of disease-associated targets that are present in their native conformation inside a mammalian cell. Curve isdeploying this platform to build a pipeline of novel cancer drugs.

Novo Holdings is a world-leading life science investor with a focus on creating long-term value.

Investment focus

Biotechnology, Health Care, Pharmaceutical
Series A, Series B, Series C
United States, Denmark, United Kingdom

Portfolio highlights

Asceneuron — Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease. By focusing on areas of high unmet medical need, Asceneuron aspires to become a leading biotech company specialized in small molecule drug discovery for neurodegenerative diseases.Tauopathies are currently untreatable neurodegenerative diseases thatrapidly progress towards debilitating conditions. The appearance of deposits of the microtubule-associated tau protein as e.g. neurofibrillary tangles in neurons of the brain is a common feature of tauopathies that is shared with Alzheimer’s disease. Neuronal tau deposits are known to be a major contributor to neurodegeneration and mutations in the tau gene are causative of the tauopathy fronto-temporal dementia and parkinsonism linked to chromosome 17 (FTDP-17).Due to increasing life expectancy, Alzheimer’s disease is viewed as one of the largest healthcare problems of this century, imposing a major economic burden on societies in the Western and developing world. Current treatment options provide limited benefits supporting the urgent need for more efficacious and better tolerated medicines that address symptomatic relief as well as disease progression.
Draupnir Bio — Draupnir Bio is developing new innovative therapies for patients.
Myricx Bio — Myricx Pharma is a small molecule drug discovery company engaged in developing novel proprietary inhibitors of human N-myristoyltransferases (NMT), with a primary focus in oncology but also exploring potential applications across other diseases.

Newable: Helping over 20,000 businesses thrive annually with tailored financial products, advice, and flexible workspace solution

Investment focus

Software, Health Care, Biotechnology
Seed, Funding Round, Series A
United Kingdom, United States

Portfolio highlights

Delta g — Delta g Limited is a quantum technology and gravity gradiometry company. A spin-out from the University of Birmingham our technology has applications in industries as varied as civil engineering, infrastructure, defence, rail, navigation and resource exploration. Experts from science, engineering an
Weldfast — Weldfast is a manufacturer and supplier of welding consumables, abrasives, chemicals, premium gas equipment, and safety products.
EarSwitch — Empowering new ways to control and connect with the world through in-ear biometric switch and sensor technology

Idinvest Partners is a pan-European private equity manager focused on the low and middle-market segments. With over 6 billion euros under management, the company has developed several complementary areas of expertise, including equity investments in buyout deals focusing on both mid-size as well as young innovative European companies; primaryinvestments in European private equity funds focusing primarily on the middle market segment; secondary investments; mezzanine investments in Europe; and private equity consulting.Idinvest Partners’ recent success stories include Criteo, Clear2Pay, Meetic, Prosensa, Converteam, Kwik Fit, Lastminute.com, Dailymotion, Deezer, Talend, Synthesio, Menlook, Vestiaire Collective, Pretty Simple, Curse.com, Withings, Kantox, Secret Escapes, Happn, Peakon, Dayuse, Botify, Financefox, Azalead and many more.

Investment focus

Biotechnology, Health Care, Software
Series B, Series A, Funding Round
France, United States, Spain

Portfolio highlights

Corti — Corti offers a digital assistant, augmenting medics in improving patient outcomes and internal performance.
Coave Therapeutics — Coave Therapeutics is active in the field of gene therapies in rare ocular and CNS (Central Nervous System) diseases.
Stilla Technologies — Stilla Technologies is taking digital PCR to a whole new level with a unique 6-color target detection capability

Speak with our Entrepreneurship Team, who can help you find sources of finance, engage with funders and secure investment to grow your business.

Investment focus

Software, Biotechnology, Information Technology
Funding Round, Seed, Series A
United Kingdom, United States, France

Portfolio highlights

Bio-Images Drug Delivery — BDD Pharma combine drug delivery expertise and clinical capabilities to accelerate product development pipelines, enable life cycle management and new innovative pharmaceutical products. Rapid parallel clinical testing with SWIFT significantly reduces time from product concept to clinical success.
IOTech — Discover IOTech Systems, the open edge data platform for developing, deploying, and managing Industrial Edge applications at scale. Find out more here.
Administrate — Manage 100% of enterprise training operations with configurable training management software, designed to scale with your organization.

Scotland's business advice, support and funding agency. Explore our products and services to find the right support for your business and apply online today.

Investment focus

Biotechnology, Software, Health Care
Grant, Funding Round, Seed
United Kingdom, United States, Japan

Portfolio highlights

MiAlgae — MiAlgae is a new-age microalgal production company that aims to revolutionize the £340 billion global livestock feed industry by producing microalgal products – through the remediation of wastewater – as nutrient supplements for fishmeal in livestock feeds. Their microalgal products are high in omegas and proteins, both of which are required forthe production of many livestock feeds, especially in the aquaculture sector.Their production methodology uses circular economy to reduce the operating costs involved in the production of microalgae and as such allows them to compete with other supplements currently on the market.
Solasta Bio — Solasta Bio develops environment-friendly products that meet a global need for new and effective crop protection.
ILC Therapeutics — ILC Therapeutics Ltd is an early-stage biotechnology company focused on modulating the Innate Immune System through the development of novel peptide therapeutics for the treatment of Covid-19, Cancer, Atopic Dermatitis, and Psoriasis.

Enterprise Ireland is the government agency responsible for the development and funding of the indigenous business sector. Their mission is to accelerate the development of companies to achieve strong positions in global markets resulting in increased national and regional prosperity. It was founded in 1998 and headquartered in Dublin, Ireland.

Investment focus

Software, Health Care, Information Technology
Funding Round, Seed, Series A
Ireland, United States, United Kingdom

Portfolio highlights

Imvizar — Imvizar focuses on life-size, location-based experiences that allow users to feel as if they've gone back in time, meeting renowned individuals and witnessing historical events all from the comfort of their own phone. Imvizar was founded by Michael Guerin and is located in Dublin, Ireland.
Contenseo — Contenseo is a copyright exchange platform that allows copyright holders and individuals looking to reuse their work to simply connect and license their property.
Tao Climate — Carbon removal services. We use hemp, sustainable housing, and nextgen MRV to deliver fast, measurable impacts on climate and society.

The Boehringer Ingelheim Venture Fund is the strategic venture fund of the Boehringer Ingelheim Corporation.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Seed
United States, Germany, Belgium

Portfolio highlights

Actym Therapeutics, Inc. — Actym Therapeutics is developing key biotech to help target intractable immune pathways in the tumor microenvironment.
Glox Therapeutics — Developing novel precision antibiotics based on protein bacteriocins, to target Gram-negative Antimicrobial Resistant (AMR) pathogens.
Asgard Therapeutics — Asgard Therapeutics is a private biotech company exploring the application of direct cell reprogramming technologies for cancer immunotherapies. Formed as a spin-off from Lund University, the Company is pioneering a gene therapy approach based on its proprietary TrojanDC technology, designed to set in motion immune responses based on the biologicalproperties of professional antigen-presenting cells.

R42 Group is a venture fund and an institute which invents, invests and informs covering AI, deep science, 5G mobile, biotech and fintech.

Investment focus

Biotechnology, Health Care, Information Technology
Seed, Funding Round, Pre-Seed
United Kingdom, United States, Austria

Portfolio highlights

Healx — At Healx we use AI drug discovery to develop new treatments for rare diseases. We bring treatments from prediction to patient.
xWatts — xWatts is an intelligent energy management software that reduces energy costs and emissions in commercial buildings.
Senisca — Developing a new generation of senotherapeutic interventions to target the diseases and aesthetic signs of ageing.

Deepbridge is a different kind of investment manager. They work closely with financial advisers and investors to design innovative products, ranging from investment in technology growth companies to asset-backed renewable energy projects. They also partner with innovative and committed management teams to help UK based companies realise theirpotential and become successful leading-edge businesses.

Investment focus

Health Care, Biotechnology, Medical
Seed, Funding Round, Series A
United Kingdom, Australia, Singapore

Portfolio highlights

AI-Sight — AI-Sight is a startup that is developing an AI diabetic retinal screening system to deliver WHO-recommended diabetic eye screening services.
Microplate Dx — Safeguarding against the spread of antimicrobial resistance worldwide.
GenoMe Diagnostics — GenoME Diagnostics - We are developing a blood test for an earlier and more accurate diagnosis of ovarian cancer.GenoME Diagnostics .

The seed investor High-Tech Gründerfonds (HTGF) finances tech start-ups with growth potential and has supported more than 700 start-ups since 2005. With the launch of its fourth fund, HTGF now has about 1.4 billion euros under management. Its team of experienced investment managers and start-up experts support young companies with expertise,entrepreneurial spirit and passion. HTGF’s focus is on high-tech start-ups in the fields of digital tech, industrial tech, life sciences, chemistry and related business areas. To date, external investors have injected about 5 billion euros of capital into the HTGF portfolio via more than 2,000 follow-on financing rounds. In addition, HTGF has already successfully sold shares in more than 170 companies. Fund investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries. Fund investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries.

Investment focus

Software, Information Technology, Biotechnology
Seed, Series A, Funding Round
Germany, Switzerland, United States

Portfolio highlights

Samp — Samp accelerates modernization and de-risks contracts by connecting outdated drawings with current 3D reality captures of your facilities using our AI.
become.1 — become.1 is an employee benefits platform that eliminates the complexity of tax regulations for employees.
Symphera — An all-in-one surgical system that makes minimally-invasive procedures more efficient.

The AIB Seed Capital Fund was established in 2007 to provide venture capital for companies at the seed and early stages of development across a range of sectors throughout the Republic of Ireland. The Fund was established under the Enterprise Ireland Seed and Venture Capital Programme 2007-2012.The Fund has a total of â‚¬30m under managementwith AIB and Enterprise Ireland both committing â‚¬15m. It is managed by experienced managers with extensive expertise in making seed and early stage investments, adding value and facilitating business success.The Fund managers are empowered to make seed investments of up to approximately â‚¬500,000. Furthermore, the Fund has the capacity to make investments in later rounds to support the continued growth of investee companies.The Fund will be managed by Enterprise Equity Venture Capital and the Dublin Business Innovation Centre. This unique partnership brings together extensive regional and investment expertise.Enterprise Equity will evaluate and manage all investments outside the city and county of Dublin, as well as investments that require in excess of â‚¬250,000 from the fund within the city and county of Dublin.Dublin Business Innovation Centre (DBIC) will evaluate and manage all investments within the city and county of Dublin when the initial investment amount required from the Fund does not exceed â‚¬250,000.

Investment focus

Software, Health Care, Medical
Seed, Funding Round, Series A
Ireland, United States, Jersey

Portfolio highlights

NewsWhip — The only real-time media monitoring platform that predicts the stories and topics that will matter in the hours ahead.
Offr — Offr is the new way to buy and sell property, quickly and transparently.
Metabolomic Diagnostics — Metabolomic Diagnostics is a deep-tech company specialized in the development of novel biomarker based diagnostic solutions for complex diseases. The company has developed an effective pipeline to firstly identify diagnostic biomarker panels and then translate these panels into clinical assays ready for application in the clinical laboratory.Thispipeline combines the biomarker multiplexing capabilities of Mass Spectrometry, a powerful analytical technology, with the company’s own informatics and statistics solutions to deliver diagnostic innovation. This is reflected in Metabolomic Diagnostics’ strong and versatile IP portfolio of technical innovations and biomarkers.Our VisionMetabolomic Diagnostics’ primary vision is to develop a portfolio of diagnostic solutions which can determine, early in a woman’s pregnancy,her risk of developing major complications much later in her pregnancy and thus enabling personalized care, adapted to each woman’s individual needs. Pregnancy complications like preeclampsia, gestational diabetes, preterm birth, and in-uterine growth restriction, all have the potential to severely impact on the well-being of mother and child.The company’s innovative diagnostic solutions will assist clinicians in re-imagining how these conditions are managed: our novel risk assessment tools are specifically developed in conjunction with prenatal care providers to ensure they make a difference that really matters. This in turn will enable clinicians to improve pregnancy outcomes globally.Our solutions will empower pregnant women: accurate pregnancy risk information will allow a pregnant woman, in partnership with her care provider, to determine what prenatal care is best for her pregnancy.

Epidarex Capital invests in early-stage, high growth life science and health technology companies in under-ventured markets. Its international team is led by Sinclair Dunlop, Kyp Sirinakis and Liz Roper. With offices in the United States and United Kingdom Epidarex Capital’s investors represent a cross-section of leading universities, internationalcorporations, development agencies and financial institutions. Epidarex was created to meet the need for more sector-specific financial backing for young companies, including spin-outs from leading research universities.

Investment focus

Biotechnology, Therapeutics, Health Care
Series A, Seed, Series B
United Kingdom, United States, Germany

Portfolio highlights

Theolytics — Theolytics is a biotechnology company harnessing viruses to combat cancer. A step-change in the oncolytic viral therapy field, our phenotypic screening Platform enables the discovery and development of efficacious, targeted candidates suitable for intravenous delivery and optimised for a chosen patient population. In addition to advancing aninternal Pipeline of programs spanning both solid and liquid tumours, we are establishing select strategic partnerships to expand and accelerate pipeline development.
Curve Therapeutics — Curve has developed an innovative screening platform that is transforming the discovery of first-in-class therapeutics. The platform allows functional screening of diverse, genetically encoded Microcycle™ libraries against a broad range of disease-associated targets that are present in their native conformation inside a mammalian cell. Curve isdeploying this platform to build a pipeline of novel cancer drugs.
Enterprise Therapeutics — Enterprise Therapeutics is a drug discovery company dedicated to the researchand development of novel therapies for the treatment of respiratory diseases.In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlyingmechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.

Noshaq offers financial services to help businesses develop.

Investment focus

Biotechnology, Health Care, Medical
Seed, Series A, Funding Round
Belgium, France, Germany

Portfolio highlights

Veoware — More coverage, shorter revisit time. Increasing target collection frequency through modular next-gen actuator technology.
Get Your Way — Discover the future of assisted reality with Get Your Way's aRdent smart glasses. Perfect for SMEs looking for innovative solutions to improve their business
Brenus Pharma — Brenus Pharma is an allogeneic platform to generate immune therapy ambitioning to harness patient immune system & prevent cancer resistance over treatment.

Omnes, "Powering Entrepreneurs" is a Leading private equity firm dedicated to energy transition and innovation.

Investment focus

Software, Biotechnology, Health Care
Series A, Funding Round, Series B
France, Germany, United States

Portfolio highlights

Qantev — Qantev is the leading AI claims platform for health & life insurance, enabling insurers to automate claims operations, reduce leakage, improve loss ratios, enhance data quality, and elevate customer experience.
Carbyon — Carbyon is a Netherlands-based company that develops direct air capture (DAC) technologies. The company's fuels help to replace fossil hydrocarbons with electrical batteries or hydrogen (H2), alternative energy carriers that are used to store renewable electricity and make major changes to transportation facilities, energy grids, and gastransportation networks, filters CO2 from the air and supply it in a purified form to make kerosene for aircraft, enabling existing fossil industry to re-use and repurpose these storage and transport facilities for renewable hydrocarbons.
Unseenlabs — Unseenlabs designs and develops a spectrum surveillance payload which is designed to detect and track non-cooperative vessels wherever they happen to be in the world.

The IFB Innovationsstarter is an innovation funding and investment company of the City of Hamburg providing grants and investments.

Investment focus

Software, SaaS, Artificial Intelligence
Seed, Funding Round, Grant
Germany, United States

Portfolio highlights

3D Spark — Profitability and Sustainability Aligned using 3D Spark's Platform - Empowering Manufacturing with Insights and Efficiency!
Stargazr — Stargazr is a AI-powered software that enables you to understand your financial data
Neuralfinity — Neuralfinity provides computer AI services. They generalise machine learning models by utilising an ML API as a service.

Amino Collective is an institutional venture capital firm investing at seed stage in health and bio companies. They help bring life-changing ideas to life by backing, connecting, and advancing our collective of entrepreneurs and scientists. The firm intends to invest in the sectors of biology, biotech, health tech, science, digital health, lifescience, and synthetic biology.

Investment focus

Health Care, Biotechnology, Software
Seed, Series A, Pre-Seed
United States, Germany, United Kingdom

Portfolio highlights

Rivia — Integrated Clinical Trial Intelligence. Drive therapeutic evaluation and trial management with real-time insights.
ExpressionEdits — Redefining the status quo of protein expression
Tandem Health — Focus on providing care, while Tandem helps you easily write medical notes directly after the patient consultation.

Coparion provides venture capital to accelerate momentum and growth. With a currently active fund of EUR 275 million, Coparion has the means to do so.Coparion supports entrepreneurial vision with know-how, but without intervening in daily business operations. Thanks to in-depth experience in venture capital and in building companies, the Coparionteam discerns potential and opens up new perspectives. Coparion has the substance, tenacity, and creativity required to mutually manage difficult situations successfully.Coparion only invests with co-investors. The fund invests up to EUR 15M per company, usually in several financing rounds of EUR 0.5-8M each. The investment focus is on German companies in the start-up and early growth phases. Coparion is based in Cologne and Berlin.

Investment focus

Software, SaaS, FinTech
Series A, Seed, Series B
Germany, Switzerland, United States

Portfolio highlights

Finoa — Finoa is the leading European crypto-asset management platform, empowering businesses and institutions to engage with crypto safely and intuitively.
Protembis — ProtEmbo is designed to be a simple and reliable solution for one of the most feared complications during TAVR.The advent of transcatheter treatments for valvular heart disease has been a major revolution in the care of patients with disabilities or intercurrent illnesses that precluded undergoing stressful open cardiac surgical procedures.Nonetheless, in spite of ongoing improvements in TAVR procedures and outcomes, the occurrence of cerebrovascular events represents a significant morbidity of TAVR.Protembis was founded based on the vision to reduce the risk of cerebrovascular events, thereby improving outcomes and making TAVR even safer – especially in light of TAVR shifting to younger and lower-risk patients. The ProtEmbo System is an adjunctive device used during TAVR and removed following completion of valve implantation. The ProtEmbo is an intra-aortic filter device that is designed to deflect embolic material arising during TAVR away from the cerebral circulation.
Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and

Amadeus Capital Partners, Venture Capital For Technology Companies. We Back Entreprenuers To Win. Contact Our Experienced Team Of Investors Today

Investment focus

Software, Artificial Intelligence, Information Technology
Series B, Seed, Series A
United Kingdom, United States, Spain

Portfolio highlights

PhoreMost — PhoreMost is a new-model drug discovery company based in Cambridge, UK: Using its core expertise to open up new ‘druggable’ target space and working with a global network of co-invested academic and industrial collaboration partners, we aim to bring a wide array of novel ‘targeted’ therapies more efficiently to market and pass these cost savingsonto patients.
Riverlane — Riverlane's mission is to make quantum computing useful far sooner than previously imaginable, starting an era of human progress as significant as the industrial and digital revolutions.
qomodo — Intelligent IOT Embedded Security. We protect commercial or industrial IOT devices from the threats of the internet. Driven by leading intelligence and machine learning, our anomaly detection allows us to protect even the simplest IOT devices.

Formic Ventures is a diversified venture capital firm that makes early-stage investments in biotechnology startups focused on human longevity as well as technology startups and companies that make human lives more meaningful.

Investment focus

Biotechnology, Health Care, Artificial Intelligence
Seed, Series A, Funding Round
United States, United Kingdom, Hong Kong

Portfolio highlights

Turn.bio — Turn Biotechnologies is a Stanford spinout developing therapies to effectively return mature differentiated cells to a dramatically younger state leaving their differentiated identity unaltered.Turn Biotechnologies surpasses traditional approaches based on single gene/pathway manipulations and tackles the multifaceted manifestation ofcellular age at the organ, tissue, and organismal level to extend the healthspan of people. As a result, age is reset by epigenetically reprogramming cells.
cheMastery — Echo handles repetitive tasks with accuracy and precision, allowing your chemists to tackle high-value challenges.
Sampling Human — The mission of Sampling Human is to couple health related decisions to their effects at the single cell level. It is inspired by the founders’ academic and professional efforts to extend what is measurable and to derive what must be measured.The human body is a complex system that cannot be quantified exhaustively or heuristically. Clinicaldiagnosis today is an imprecise art. On average, diagnosis of rare diseases is 5 years delayed with 50% of delays impacting the outcome. Misdiagnosis is far too common with a 66% likelihood of disagreement between experts. We are stuck with symptoms based medicine.The nature of physiological data is to blame. Decisions today are based on fuzzy variables (tired, drowsy, weak, tingling, itchy, etc). Better decisions will require precise knowledge regarding the fundamental physiological units of our bodies, CELLS.

IQ Capital is a Cambridge & London-based VC firm that invests in ‘deep tech’ companies capable of dominating their respective markets on a global scale. Initial investments at Seed and Series A range from £0.5m to £10m, with capacity for follow-on investment up to £30m through the Growth Fund. The team has achieved over 30 exits including toApple, Huawei, Google and Oracle.

Investment focus

Software, Artificial Intelligence, Machine Learning
Seed, Series A, Funding Round
United Kingdom, United States, The Netherlands

Portfolio highlights

NanoSyrinx — NanoSyrinx is an award-winning, discovery stage biotechnology company based in the UK. We are using synthetic biology approaches to develop protein nanosyringes as a completely novel modality for intracellular delivery of protein and peptide biologic drugs.
Neurovalens — Neurovalens delivers innovative solutions in the field of neuroscience, bioscience and neurophysiology.Neurovalens has received support from Invest NI under the European Union’s Investment for Growth and Jobs Programme. The project, recorded on the ERDF beneficiaries’ website, will be implemented over the next one year, undertaking research anddevelopment activities aimed at improving the competitiveness of the business.
Wobble Genomics — Wobble Genomics specializes in maximizing RNA and DNA sequencing efficiency for the discovery and detection of nucleic acid biomarkers.

Paca Investissement is specializes in investing in startups and developmental stages. The fund invests in the Provence-Alpes-Côte d'Azur (PACA) region.

Investment focus

Software, Internet, Manufacturing
Seed, Funding Round, Series A
France

Portfolio highlights

GANGZ — I found a great domain name for sale on Dan.com. Check it out!
SailEazy — The SailEazy community offers all sailing enthusiasts the choice of freedom. A shared professional fleet, bases between the Atlantic and the Mediterranean ... discover a disruptive and innovative way of navigation. Throughout the year, 7 days / 7 and 24 hours a day, you can book and discover the high-performance sailboats of a professionalfleet, entirely managed by SailEazy. Subscriber, or punctual browser, autonomous or not, you have the choice. You freely determine your niche of reservation, without constraint time or duration, you choose your base of departure and your sailboat, according to your program (short exit, cruise, regatta, coastal, wide ...). Hourly pricing includes a 360 ° service keychain beyond the cost of the lease, including insurance, fuel, cleaning and equipment. Compulsive veiled, expert or contemplative, all members of the community have their way of navigating.
C4Diagnostics — C4Diagnostics developed a fast, reliable detection of microorganisms. Our Click-chemistry technology is at the core of our portfolio of diagnostic tests.

Mercia Asset Management provides equity and debt to UK businesses with growth ambition. We are your investment partners from scale-up to exit.

Investment focus

Software, Health Care, Biotechnology
Seed, Funding Round, Series A
United Kingdom, United States, Hungary

Portfolio highlights

Kuano — Kuano provides innovative quantum and AI solutions for drug discovery and design. It offers a discovery platform that combines target quantum mapping and AI-led chemistry to enable the faster development of better drug candidates.
MGISS — Independently advising on the smarter use of Geospatial data, technology and the digital transformation of field operations.
Workbuzz — Give your Everyday Heroes a voice with employee engagement surveys. Our flexible and simple survey platform reaches all employees, wherever they are. Book a demo now!

ENISA is a public company under the Ministry of Industry, Energy and Tourism, through the Directorate General of Industry and Small and medium-sized enterprises which, since 1982, actively participates in the financing of viable and innovative business projects.

Investment focus

Software, Health Care, E-Commerce
Seed, Debt Financing, Pre-Seed
Spain, United States, France

Portfolio highlights

Joppy — Joppy is a recruitment platform.
Banktrack — Banktrack provides All the bank movements by Email, WhatsApp, or your favorite channel.
Identify Travel — Identify Travel is a travel arrangements company that creates unique itineraries, incorporates cultural events, and provides the finest gastronomic offer via a digital map to ensure that customers have a pleasant vacation experience.

Helping individuals and institutions invest in Venture Capital, Infrastructure and Media companies since 1999.

Investment focus

Software, Health Care, Biotechnology
Funding Round, Seed, Series A
United Kingdom, United States, France

Portfolio highlights

Ittybit — Ittybit is a API that enables users to handle rich media in applications. It provides developers with basic techniques for uploading, storing, transforming, and extracting data from video, music, and image files.
HealthKey — HealthKey is a platform that connects employers and insurers with health providers.
Noggin HQ — The next generation of credit referencing is coming. Look busy.

Southern Angel Investors Club, combining Surrey investors Club & Angels 5K, are entrepreneurs who understand what new businesses need.

Investment focus

Biotechnology, Software, Medical
Seed, Funding Round, Angel
United Kingdom

Portfolio highlights

Celixir — Celixir is a developer of regenerative medicines created to change the lives of patients in need. The company's medicines consists of iMP cells, platelet lysate and PML cells to treat patients with ischaemic heart disease, injured tendons near the surface of the skin and mild to moderate heart failure respectively, enabling medical researchersto discover breakthrough medicines that aim to change the standard of medical care for patients.
Novastone Media — With its unique asymmetric technology, novastone puts you directly where your clients want to talk to you.
Geektastic — Geektastic guarantees hiring teams only meet high calibre candidates. Our technical code challenges quickly identify the most talented software engineers.

Techstart Ventures is a leading investor of seed capital across Scotland and Northern Ireland. they are a trusted partner to ambitious founders on their journey to success.

Investment focus

Software, Health Care, Information Technology
Seed, Pre-Seed, Funding Round
United Kingdom, Ireland

Portfolio highlights

Obbi Golf — Integrating Compliance, Safety and Quality across your Golf Club. Integrate greenkeepers, hospitality, pro shop and management.
loveelectric — loveelectric is on a mission to halve the cost of motoring
Desana — Seamlessly integrate existing assets into a global network of flexible workspaces and meeting rooms so staff can work from quality environments. Wherever.